RASSF1 and neoplasm: In a multivariate analysis including age, sex and tumour stage, serum RASSF1A methylation was still associated with poor outcome with a hazard ratio of 2.4 (95% CI, 0.6–9.2), although this did not reach statistical significance (P=0.194; Table 5).